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Abstract
Background: Depression and anxiety are correlated with greater nicotine dependence, smoking persistence, and
relapse back to smoking after a quit attempt. Menthol cigarette smoking, which is prevalent in young adults, is
associated with nicotine dependence, progression to regular smoking, and worse cessation outcomes than
non-menthol smoking. Few have established a link between menthol tobacco use, beyond just smoking,
with mental health in this high-risk age group. This study examined the association of menthol tobacco use
to anxiety and depression in a national sample of young adults.
Methods: Data were from Waves 1 through 7 (n = 9720, weighted) of the Truth Initiative Young Adult Cohort,
a national sample of men and women aged 18 to 34 assessed every 6-months. Demographics, past 30-day use
of non-menthol and menthol tobacco products, and current alcohol, marijuana, and other drug use were assessed
among those with depression and anxiety.
Results: Thirty nine percent of current tobacco users used menthol as their preferred brand. Using a cross-sectional
analysis (collapsed across waves), past 30-day menthol tobacco was uniquely associated with greater odds of both
depression and anxiety, beyond the effects of demographic and substance correlates and non-menthol tobacco
product use.
Conclusions: Menthol is disproportionately used among young adults tobacco users with mental health problems,
above and beyond the impact of a variety of other mental health and tobacco use risk factors. Findings suggest a
strong link between menthol tobacco use and poor health outcomes. Policies should be developed to deter menthol
tobacco use in vulnerable groups.
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Background
Menthol comprises nearly a third of the tobacco market.
It’s minty taste and cooling and anesthetizing properties
have been posited to reduce the harshness of smoke in-
halation, may contribute to tobacco use and smoking
initiation in young people [1–4], and may prevent to-
bacco users from quitting [5–7]. While recent data show
decreases in the prevalence of non-menthol cigarette
smoking [6, 8] there has been an increase in menthol
cigarette use in young adults during this same time
period [9]. Menthol has been proposed as an important
factor in the transition from initiation to regular tobacco
use during young adulthood [3, 4].
Menthol may increase the addictive potential of to-
bacco use via multiple mechanisms, including bio-
logical, genetic, environmental, and dispositional [10–16].
Menthol tobacco use may be maintained through its asso-
ciation with positive, pleasurable, and other hedonistic re-
sponses to nicotine. This may attract new users [3, 4] and
facilitate greater ingestion of harmful tobacco constituents
[11]. Further, the highly salient positive sensory properties
of menthol may enhance the overall rewarding effects of
nicotine reinforcement [12, 17], thereby strengthening the
uptake of cigarette or other nicotine-containing tobacco
products among emergent users. This then enhances the
addiction potential of menthol tobacco products, and may
hinder success at quitting later on [18].
Psychiatric distress, including depression and anxiety,
is linked to tobacco use, greater nicotine dependence,
smoking persistence, and poor smoking cessation out-
comes [19–22]. Similarly, menthol cigarette smoking has
consistently been associated with more severe nicotine
dependence [23] and lower quit rate success than non-
menthol smokers [24–26]. A paucity of published re-
search, however, has focused on the link between mental
health factors and menthol cigarette and other tobacco
product use in young adult populations, despite the ex-
ceedingly high rates of menthol tobacco use in this age
group. Of the few studies published linking menthol use
to mental health, findings show that the prevalence of
menthol cigarette smoking is high among those with se-
vere psychological distress compared to those without
[11, 27, 28] and that menthol smokers report worse gen-
eral mental health than non-menthol smokers [29, 30].
One recent population-based study of young adults
found that menthol cigarette smoking was correlated
with marijuana use and binge drinking [31], two health-
risk behaviors that are also robustly linked to psychiatric
distress [32–37]. One explanation for the association be-
tween menthol cigarette smoking and mental health
problems could be due to the cooling sensation of men-
thol, which has a mildly arousing and stimulating effect
[38], and may dampen frequent or chronic dysphoric
mood often present with certain mental illnesses.
Indeed, prior research shows that menthol cigarettes are
used to enhance drug-related high and to sustain
euphoric mood states [39]. Other research suggests that
the nicotine in tobacco, more generally, is used to self-
medicate mood disorders [36, 40]. If this was the case,
then menthol tobacco use would not be differentially
associated with mental health problems, compared to
non-menthol tobacco use. Taken together, the stimulating
and arousing properties of menthol in nicotine-containing
tobacco products might be attractive to young adults with
mental illnesses, perhaps to self-medicate and cope with
negative mood states. If menthol increases the subjective
effects of nicotine on mood improvement, one might ex-
pect greater uptake of menthol tobacco products in young
adults with mood problems than those without.
In sum, mental health problems and menthol cigarette
smoking have been robustly linked to smoking persist-
ence, nicotine dependence, and poor smoking cessation
rates [20, 41]. Further, a high prevalence of menthol
cigarette use has been documented among young adult to-
bacco users [8, 42, 43]. As such, it would be important to
determine whether menthol tobacco use is associated with
increased mental health problems in this age group. Such
findings may explain, in part, why menthol cigarette use is
correlated with smoking initiation and progression in
young people – it is being used to self-medicate or cope
with stress and emotional problems. Further, because
young adults use a variety of tobacco products, not just
cigarettes [44], it would be important to examine the asso-
ciation of all types of menthol tobacco products, beyond
cigarettes, to mental health problems. This study used a
national sample of over 9600 young adults to examine the
prevalence of depression and anxiety as a function of
menthol tobacco product use, after adjusting for demo-
graphic and psychosocial risk factors known to impact
both mental health and tobacco use (i.e., alcohol, drug
use). We hypothesized that menthol tobacco use would be
associated with increased mental health risk, above and
beyond the impact of other robust mental health and
tobacco use risk factors. Additionally, because this study
examines the association of menthol tobacco use with de-
pression and anxiety, above and beyond other mental
health and tobacco use risk factors, we also describe the
links between these risk factors and the outcomes of inter-
est, to situate our primary hypothesis in context. Such
findings would suggest that removal of menthol tobacco
products from the tobacco marketplace may prevent initi-
ation and progression to regular use among particularly
vulnerable groups of incipient users.
Methods
Sample
Data were from Waves 1 through 7 of the Truth Initia-
tive Young Adult Cohort, a national sample of men and
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women aged 18 to 34 drawn from the GfK Knowledge-
Panel®. Waves were assessed at approximately 6-month
intervals, from June 2011 (Wave 1) to October 2014
(Wave 7). KnowledgePanel® is an online panel of adults
ages 18 and older that covers both the online and offline
populations in the U.S (http://www.gfk.com/products-a-
z/knowledgepanelr-northamerica/). The panel was re-
cruited via address-based sampling, a probability-based
random sampling method that provides statistically valid
representation of the U.S. population, including cell
phone-only households. Households without internet ac-
cess were provided a free netbook computer and inter-
net service to reduce response bias in typical online
survey samples. African-American and Hispanic individ-
uals were oversampled. The validity of this methodology
has been reported previously [45–50].
The panel recruitment rate ranged from 14-15 %
across all waves [51]. In 64-66 % of these identified
households, one member completed a core profile sur-
vey in which the key demographic information was col-
lected (profile rate). For this particular study, only one
member per household was selected at random. The re-
sponse rate ranged from 29-55 % and the cumulative re-
sponse rate across all surveys ranged from 4-7 %, which
is consistent with other published studies [52, 53].
After Wave 1, the sample for each wave consisted
of people who completed the previous wave plus a
refreshed sample to replace individuals lost to follow-
up and to ensure the sample did not age out of the
cohort. This study was approved by the Independent
Investigational Review Board, Inc. for Waves 1-3 and
Chesapeake Institutional Review Board, Inc. for Waves 4-
7. Additional details on survey methodology have been
published elsewhere [54]. The present analysis focused on
a subset of 9658 (weighted n = 9720) young adults aged 18
to 34 at study entry who answered questions on mental
health and contributed 26,378 (weighted n = 26,587)
cases/observations over seven waves of data collection.
Measures
Mental health symptoms
As the primary outcomes, two variables were created to
assess symptoms consistent with current (past 2 weeks)
depression and anxiety from the two-item Patient Health
Questionnaire (PHQ-2) [55, 56] or the two-item General-
ized Anxiety Disorder (GAD) scale [57, 58], respectively.
Using a 4-point scale (0 = “not at all” and 3 = “nearly every
day”), PHQ-2 queries about the frequency of depressed
mood and loss of interest in pleasant activities, while the
two-item GAD queries about the frequency of uncontrol-
lable worry and feelings of anxiety. According to validated
scoring guidelines [56, 58], individuals who received a
score at or above the cut-off (≥3) were coded as having
either depression or anxiety at that particular wave.
Tobacco use
At each wave, participants were asked about past 30-day
use of eleven tobacco products including: cigarettes,
cigars, pipe, little cigars/cigarillos (LCCs), e-cigarettes,
chewing tobacco, dip/snuff, snus, dissolvable products,
hookah/shisha, and other nicotine products (i.e., gum,
patches, lozenges). Participants who reported use of any
tobacco product in the past month were defined as past
30-day tobacco users in that particular wave. For each
product used, participants were asked to identify the
typical brand used in the past 30 days and whether it
was menthol-flavored. Participants who reported that
their typical brand was mentholated were defined as a
current menthol tobacco user in that particular wave.
Following established methods [59, 60], examples of
usual brands were included in the question to further as-
sist with the query. Past 30-day non-menthol tobacco
use and past 30-day menthol tobacco use are wave-
specific variables. Thus, an individual could be both a
past 30-day tobacco user and not a past 30-day menthol
tobacco user, depending on the wave.
Alcohol, marijuana, other drug use
Current alcohol use was assessed differently for Waves
1-6 versus Wave 7. In waves 1-6, all participants were
asked about the frequency of their current use, with re-
sponse options “every day,” “some days,” and “not at all.”
Those who reported using alcohol “some days” or “every
day” were defined as current users in that particular
wave. For wave 7, current alcohol use was determined
by two items. The first item asked about frequency of
drinking alcohol in the past year (“never,” “monthly or
less,” “2-4 times per month,” “2-3 times per week,” “4 or
more times per week”). Those who reported any use of
alcohol were then queried about the frequency of use in
the past 30 days, with respondents using ≥1 days in the
past month defined as current users. Those with missing
data (<2 %) were defined as non-current users in that
particular wave.
For current marijuana and other drug use (cocaine,
ecstasy, meth, etc.), participants were asked about the
frequency of their use for each substance, with response
options “every day,” “some days,” and “not at all,” simi-
larly across all waves. Those who reported current use
some days or every day were defined as current users in
that particular wave. Those with missing data or who re-
ported “not at all” (<2 %) were defined as non-current
users in that particular wave.
Demographics
Participants provided information on age at study entry
(grouped as 18-24 and 25-34), gender, race/ethnicity
(White, non-Hispanic; Black, non-Hispanic; Other, non-
Hispanic; and Hispanic), highest education completed
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(less than high school, high school, and some college or
greater), and financial situation (does not meet basic needs,
just meets basic needs, meets needs with a little left, and
lives comfortably). Financial situation was assessed at
Waves 1, 3, 5, and 7; and was imputed using a carry-
forward approach from the previous wave for waves 2 and
4 and a carry-backward approach for wave 6 [61, 62].
Analyses
Analyses were performed using Stata/SE 13.1 (StataCorp,
2014) in April 2015. Post-stratification weights were
used to offset non-response or non-coverage bias and to
produce nationally representative estimates specific to
each wave. Our main hypothesis was not focused on the
impact of menthol use on changes in depression and
anxiety over time. Preliminary analyses of the intra-class
correlations (ICCs) did not show significant variations
over time in prevalence of depression or anxiety, there-
fore data were collapsed across the 7 study waves. That
is, because prevalence estimates of depression and anx-
iety at each time point were not statistically different, we
collapsed data across all observations at each wave. To
account for clustering of individual responses over time,
participant ID was set as the primary sampling unit in
all analyses and study wave was included as a covariate
in analyses. The robust Poisson regression method was
used to adjust for inflation of the odds ratio, given that
the prevalence of the outcomes were higher than 10 %
(i.e., the recommended standard) of the total sample [63].
We calculated the prevalence of anxiety and depres-
sion in the sample. Bivariate modified Poisson regres-
sions were then conducted to examine correlates of
anxiety and depression. Next, we examined overall
changes in prevalence ratios of the association of past
30-day menthol tobacco use on anxiety or depression
after covariate adjustment. To do this, three separate
multivariable modified Poisson regression models were
conducted (separately for each outcome) that included
demographics in step 1; demographics, tobacco, and
substance use variables entered in step 2; and the
addition of menthol-flavored tobacco use in step 3.
Because data are collapsed across waves, modified
Poisson regression prevalence ratios represent the asso-
ciation of a person at a specific time point, reporting
that they were a menthol or non-menthol user (for ex-
ample). All models controlled for study wave and miss-
ing data were handled with modelwise deletion per
Stata’s survey procedures. Missing data values are re-
ported in Table 1.
Results
Prevalence and correlates of anxiety and depression
The sample (see Table 1) was composed of equal numbers
of men and women, with the majority aged 18- 24 (60 %),
White, non-Hispanic (58 %), having at least some college
education (61 %), and a little over a third met financial
needs with a little left over (38 %). Overall, 13 % of the
sample reported symptoms consistent with current de-
pression and 15 % reported symptoms consistent with
current anxiety. Almost half (45 %) of those who reported
depression or anxiety endorsed symptoms consistent with
both mental health issues. Of the total sample, 58 % were
current alcohol users, 24 % were past 30-day tobacco
users, 13 % were current marijuana users and 2 % were
current users of other drugs. Of those who were past
30-day tobacco users, 39 % used menthol as their
preferred brand (of at least one tobacco product).
A sub-analysis (not reported in Table 1) was con-
ducted to examine menthol use across race. Among past
30-day tobacco users in the study sample, 67 % of Black
respondents reported current use of menthol tobacco,
followed-by 45 % of non-Black, non-Hispanic, 44 % of
Hispanic, and 32 % of White respondents (p < 0.001).
Crude prevalence ratios from bivariate modified
Poisson regression models showed that females, those
with less than a high school education (vs. some col-
lege or greater), and those with financial situations
that at most just met basic expenses (vs. meeting
needs with a little left) were more likely to report de-
pression or anxiety (all p’s < 0.05).
Race, education, and financial situation varied across
the mental health outcomes. Non-White respondents
were more likely to report depression, but not anxiety
(all p’s <0.05). Those with a high school education
(vs. some college or greater) were significantly more
likely to report symptoms of depression, but not anx-
iety (p <0.001). Those who reported living comfort-
ably (vs. meeting needs with a little left) were less
likely to report anxiety (p =0.020). Depression appeared
unrelated to financial situation (p =0.071). Age was not as-
sociated with depression or anxiety (p’s 0.30 - 0.60).
Current users of tobacco, marijuana, and other
drugs were more likely to report depression and anx-
iety compared with non-users (all p’s <0.001). Current
alcohol users were more likely to report symptoms of
anxiety (p =0.014), but not depression (p =0.404). Al-
most 25 % of respondents who reported past 30-day
menthol tobacco use also reported anxiety or depression
(Table 1). Within the full sample, however, only ~10 % of
respondents reported past 30-day menthol tobacco use.
Stepwise modified Poisson regression models
Table 2 shows correlates of current anxiety across all
step-wise three models. Adjusting for all covariates in
the final model (Model 3), past 30-day use of any men-
thol tobacco product emerged as a significant correlate
of current anxiety. Female gender and lower financial
means remained significantly associated with increased
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odds of anxiety after including all variables in the model
(Model 3). Past 30-day tobacco use, current marijuana
use, and current other drug use also remained signifi-
cantly correlated with anxiety in the final model.
Table 3 shows correlates of current depression across
all three models. Similar to the model for anxiety, adjust-
ing for all covariates in the final model (Model 3), past
30-day use of any menthol tobacco product still emerged
as a significant correlate of depression. Also, in the final
model, Hispanic respondents and non-Black, non-
Hispanic respondents were significantly more likely to
report depression compared to White, non-Hispanic re-
spondents in the final model. Similar to the model for
anxiety, lower financial means was significantly associ-
ated with depression in the final model. Finally, after
adjusting for all covariates in the final models, individuals
with a high school education (vs. at least some college)
were more likely to report depression, as were past 30-day
tobacco users, current marijuana users, and current other
drug users. Age and current alcohol use were not signifi-
cant correlates of depression in the final model.
Discussion
Studies linking menthol tobacco use, beyond just cigarette
smoking, to higher rates of depression/anxiety in young
adults are scant. This study sought to uncover whether
menthol tobacco-using young adults show certain mental
health vulnerabilities relative to non-menthol users, after
controlling for other covariates known to impact both
mental health and tobacco use in this age group.
Table 1 Weighted sample characteristics by mental health status, across all waves (1-7) in n = 9720 young adults using crude
unadjusted Poisson regression
Total Anxiety Depression
Weighted N = 26,587 Weighted N = 3,870 Weighted N = 3,549
Overall 14.70 % 13.43 %
Age 18-24 (referent) 60.26 % 14.49 % 13.04 %
25-34 39.74 % 15.02 % 14.02 %
Sex Male (referent) 49.68 % 12.36 % 12.19 %
Female 50.32 % 17.01 %** 14.65 %*
Race White, non-Hispanic (referent) 58.26 % 14.37 % 11.80 %
Black, non-Hispanic 13.14 % 15.87 % 16.62 %**
Other, non-Hispanic 8.35 % 16.42 % 15.91 %*
Hispanic 20.25 % 14.19 % 15.05 %*
Education Less than high school 11.81 % 18.37 %* 16.64 %**
High school 27.13 % 15.33 % 15.69 %**
Some college or greater (referent) 61.05 % 13.72 % 11.81 %
Financial Situation Don’t meet basic expenses 7.85 % 26.90 %** 26.31 %**
Just meet basic expenses 30.97 % 18.27 %** 16.42 %**
Meet needs with a little left (referent) 37.84 % 11.86 % 10.64 %
Live comfortably 23.34 % 9.85 %* 9.16 %
Past 30-day tobacco use No (referent) 75.57 % 12.59 % 11.63 %
Yes 24.43 % 21.23 %** 19.00 %**
Past 30-day menthol tobacco use No (referent) 90.23 % 13.60 % 12.40 %
Yes 9.77 % 24.96 %** 22.93 %**
Current alcohol use No (referent) 42.55 % 13.92 % 13.36 %
Yes 57.45 % 15.28 %** 13.48 %
Current marijuana use No (referent) 87.43 % 13.19 % 12.06 %
Yes 12.57 % 25.27 %** 22.99 %**
Current other drug use No (referent) 97.54 % 13.96 % 12.77 %
Yes 2.46 % 44.14 %** 39.65 %**
Note. Unweighted respondent n = 9658. Data represent row percents. Missingness for financial situation due to lagged wave assessment was 7.0 %. Both 30-day
tobacco use and 30-day menthol tobacco use were assessed out of the full study sample. Those with missing data on alcohol, tobacco, marijuana, and other drug
use (<2 %) were defined as non-current users
*p < 0.05 **p <0.001
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Bivariate analyses showed that current menthol-
flavored tobacco users reported anxiety and depression
at a higher prevalence compared to the full sample and
to non-menthol tobacco users. Consistent with prior
research, women, those with lower educational and fi-
nancial means, and those currently using tobacco and
other drugs were more likely to report anxiety and de-
pression [64, 65]. Race was differentially associated with
depression and anxiety, such that non-White respon-
dents were most likely to report depression; however
race was unrelated to anxiety. Alcohol use was not as-
sociated with either depression or anxiety, which we
would not expect based on prior [34, 66]. Our findings
may have been due to our assessment of alcohol use,
which measured only general consumption in the past
30-days, but not consequences of use or heavy drinking;
alcohol-related problems or indices of risky drinking
behavior may be better predictors of mental health
problems.
Stepwise modified Poisson regression models revealed
that the odds of reporting anxiety and depression were
nearly two and half times greater among those not meet-
ing basic financial needs, relative to those meeting basic
needs with some additional money left over. Further
those currently using other drugs, such as cocaine,
methamphetamine, or ecstasy, had the highest risk of
anxiety and depression; nearly three times higher (for
both outcomes) relative to respondents not using other
drugs. Lastly, as we predicted, menthol tobacco use was
associated with elevated risk for both mental health
Table 2 Stepwise modified Poisson regression models of menthol use associated with current anxiety among n = 9720 (weighted)
young adults




substance use and menthol use
Predictors APR (95 % CI) p APR (95 % CI) p APR (95 % CI) p
Age
18-24 Reference Reference Reference
25-34 1.03 (0.91, 1.15) 0.679 1.03 (0.92, 1.16) 0.609 1.03 (0.92, 1.16) 0.598
Gender
Male Reference Reference Reference
Female 1.32 (1.18, 1.49) 0.000 1.41 (1.25, 1.58) 0.000 1.40 (1.24, 1.57) 0.000
Race
White, non-Hispanic Reference Reference Reference
Black, non-Hispanic 0.95 (0.77, 1.16) 0.603 0.95 (0.78, 1.17) 0.644 0.94 (0.76, 1.14) 0.515
Other, non-Hispanic 1.17 (0.97, 1.42) 0.106 1.19 (0.99, 1.43) 0.071 1.18 (0.98, 1.42) 0.087
Hispanic 0.92 (0.80, 1.07) 0.284 0.96 (0.83, 1.11) 0.594 0.96 (0.83, 1.10) 0.532
Education
Less than high school 1.17 (0.97, 1.42) 0.106 1.07 (0.90, 1.29) 0.439 1.07 (0.89, 1.28) 0.469
High school 1.02 (0.89, 1.16) 0.799 0.98 (0.86, 1.12) 0.748 0.98 (0.86, 1.12) 0.754
At least some college Reference Reference Reference
Financial Situation
Does not meet basic expenses 2.19 (1.85, 2.61) 0.000 2.01 (1.69, 2.38) 0.000 2.00 (1.69, 2.37) 0.000
Just meets basic expenses 1.53 (1.35, 1.73) 0.000 1.48 (1.32, 1.68) 0.000 1.49 (1.32, 1.68) 0.000
Meets needs with a little left Reference Reference Reference
Lives comfortably 0.83 (0.71, 0.97) 0.022 0.84 (0.72, 0.97) 0.021 0.84 (0.72, 0.97) 0.021
Past 30 day tobacco use – – – 1.43 (1.27, 1.61) 0.000 1.32 (1.15, 1.50) 0.000
Current alcohol use – – – 1.01 (0.91, 1.13) 0.818 1.01 (0.91, 1.13) 0.828
Current marijuana use – – – 1.42 (1.24, 1.62) 0.000 1.42 (1.24, 1.63) 0.000
Current other drug use – – – 2.26 (1.90, 2.68) 0.000 2.22 (1.87, 2.64) 0.000
Past 30 day menthol tobacco use – – – – – – 1.20 (1.02, 1.42) 0.029
Study Wave 1.02 (0.99, 1.04) 0.164 1.01 (0.99, 1.04) 0.208 1.01 (0.99, 1.03) 0.242
Note. APR Adjusted Poisson Regression. Wave is centered on first wave. Any individual missing data on a covariate was excluded
Those with missing data on alcohol, tobacco, marijuana, and other drug use (<2 %) were defined as non-current users
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outcomes, after controlling for a number of other risk
factors. This suggests there is something unique about
menthol in tobacco products that links it to affective
vulnerability. Such findings are concerning given the ro-
bust association between psychiatric distress, particularly
depression, with more severe nicotine dependence,
smoking persistence, and higher rates of smoking relapse
among adult tobacco users [20, 67–70]. Thus, mental
health may be one factor explaining why menthol
smokers have worse cessation outcomes and greater
nicotine dependence relative to non-menthol smokers in
some studies [7]. This has important implications for in-
cipient tobacco users with depression or anxiety. These
individuals may start their tobacco use “careers” with
menthol, but may find it exceedingly difficult to quit in
later years because of the subjective rewarding effects of
menthol [16], as well as the desire to self-medicate nega-
tive mood symptoms with nicotine [36, 40].
There could be several reasons why menthol is linked
to mental health. First, the stimulating properties of
nicotine, coupled with the positive sensory aspects of
menthol, may relieve the negative moods and other aver-
sive symptoms (i.e., weight gain, irritability, fatigue) that
are common among individuals with depression or anx-
iety [36, 40]. If nicotine was the only mood-enhancing
factor of tobacco use, then we would not have found dif-
ferences between menthol and non-menthol tobacco
users. These findings add to the literature, and suggest
that menthol tobacco has distinct properties that drives
its use among certain groups of users, and which may
Table 3 Stepwise modified Poisson regression models of menthol use associated with current depression among n = 9720
(weighted) young adults




substance use, and menthol use
Predictors APR (95 % CI) p APR (95 % CI) p APR (95 % CI) p
Age
18-24 Reference Reference Reference
25-34 1.00 (0.88, 1.12) 0.948 1.01 (0.89, 1.13) 0.907 1.01 (0.89, 1.13) 0.898
Gender
Male Reference Reference Reference
Female 1.18 (1.04, 1.33) 0.008 1.24 (1.10, 1.40) 0.000 1.23 (1.09, 1.39) 0.001
Race
White, non-Hispanic Reference Reference Reference
Black, non-Hispanic 1.17 (0.97, 1.42) 0.097 1.18 (0.98, 1.41) 0.079 1.15 (0.96, 1.39) 0.136
Other, non-Hispanic 1.38 (1.12, 1.70) 0.002 1.39 (1.13, 1.71) 0.002 1.38 (1.12, 1.69) 0.002
Hispanic 1.18 (1.01, 1.37) 0.036 1.21 (1.05, 1.41) 0.009 1.21 (1.04, 1.40) 0.012
Education
Less than high school 1.18 (0.98, 1.43) 0.083 1.10 (0.91, 1.31) 0.330 1.09 (0.91, 1.31) 0.366
High school 1.19 (1.04, 1.37) 0.011 1.15 (1.01, 1.32) 0.034 1.15 (1.01, 1.32) 0.033
At least some college Reference Reference Reference
Financial Situation
Does not meet basic expenses 2.29 (1.92, 2.72) 0.000 2.11 (1.78, 2.51) 0.000 2.11 (1.78, 2.50) 0.000
Just meet basic expenses 1.48 (1.30, 1.68) 0.000 1.44 (1.27, 1.64) 0.000 1.44 (1.27, 1.64) 0.000
Meet needs with a little left Reference Reference Reference
Live comfortably 0.87 (0.73, 1.03) 0.097 0.87 (0.74, 1.02) 0.087 0.87 (0.74, 1.02) 0.086
Past 30 day tobacco use – – – 1.33 (1.17, 1.51) 0.000 1.21 (1.04, 1.41) 0.015
Current alcohol use – – – 0.96 (0.86, 1.08) 0.539 0.96 (0.86, 1.08) 0.521
Current marijuana use – – – 1.48 (1.28, 1.71) 0.000 1.49 (1.29, 1.71) 0.000
Current other drug use – – – 2.12 (1.75, 2.57) 0.000 2.07 (1.71, 2.52) 0.000
Past 30 day menthol tobacco use – – – – – – 1.24 (1.03, 1.50) 0.021
Study Wave 0.99 (0.96, 1.01) 0.213 0.98 (0.96, 1.01) 0.147 0.98 (0.96, 1.00) 0.121
Note. APR Adjusted Poisson Regression. Wave is centered on first wave. Any individual missing data on a covariate was excluded. Those with missing data on
alcohol, tobacco, marijuana, and other drug use (<2 %) were defined as non-current users
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lead to more persistent use later on [12, 16, 17, 71]. Al-
ternatively, individuals with an underlying vulnerability
toward a variety of health-risk behaviors may self-select
to use menthol tobacco. This may be because menthol
flavoring is offered in a variety of different tobacco prod-
ucts [43] and vulnerable young adults are likely to try
many substances of abuse, not just cigarettes [72]. A
third reason could be that menthol is more likely to be
sold in neighborhoods where socially and economically
disadvantaged individuals reside, including those with
mental health problems. For example, Young-Wolff and
colleagues [27] found that tobacco retailer densities were
twice as high in areas occupied by smokers with serious
mental illness relative to the general population. Our
findings showed that individuals with lower financial
means and educational attainment were prone to mental
health problems, and thus, the link between menthol use
and mental health in young adults may be partially ex-
plained by tobacco marketing toward these lower in-
come individuals. We did not assess the impact of
tobacco marketing, nor neighborhood composition in
this study.
There were several limitations of this study. First, we
cannot conclude that menthol causes mental health
problems due to the cross-sectional nature of the ana-
lyses. Similarly, we did not examine product switching,
or the case in which someone could have been a men-
thol user at one time point, but no longer a menthol
user at a subsequent time point; although prior studies
indicate this is not common [1, 73]. Follow-up studies
can examine whether age of menthol initiation predicts
subsequent onset or progression of anxiety and depres-
sion. Second, this was a secondary analysis and we were
limited to the measurement items within the dataset.
Other factors not currently measured, such as neighbor-
hood composition and social network factors, may im-
pact rates of menthol use and mental health. Third,
rates of anxiety and depression in the present study were
higher than those reported in other national samples
[21, 22]. This is likely due to the sensitivity of our 2-item
measures. A more in-depth clinical assessment of de-
pression, anxiety, and substance use features may be
warranted [74]. Fourth, this study uses an existing online
panel to recruit a large, national cohort of young adults.
Although African American and Hispanic young adults
were oversampled to ensure sufficient sample sizes, our
sample may not be representative of the national popula-
tion of young adults. Finally, we did not examine the im-
pact of individual tobacco products (i.e.,e-cigarettes,
LCCs, hookah) on mental health outcomes due to small
sample sizes. Given the rising popularity of flavored to-
bacco use in young people [43], future work should
examine product-specific links between menthol flavor-
ing and mental health in this age group.
This study has several strengths. We are not aware
of any national studies that have examined the link of
menthol tobacco use, beyond menthol cigarette use,
and mental health in young people. Of the two large-
scale studies that have been published, both focused
on adult populations and used either a general measure of
psychiatric distress [28] or a crude measurement of well-
being [30]. Further, both focused exclusively on menthol
cigarette use, not tobacco use more generally. Examining
a broad set of menthol tobacco product use, not just
cigarette smoking, is particularly relevant to young people.
Young adults have the highest rates of tobacco product
use (cigarette and non-cigarette products) relative to any
other age group and are highly likely to use a variety of
different types of tobacco products [44]. Further, the use
of flavored tobacco products, including menthol, is par-
ticularly prevalent in this age group [43].
Conclusions
In summary, findings provide evidence that menthol is
disproportionately used by vulnerable groups of young
adult smokers, beyond the impact of other robust
mental health and tobacco use risk factors. Menthol’s
link to anxiety and depression, over and above non-
mentholated tobacco product use, and the rising preva-
lence of menthol use in young adults makes the use of
these mint-flavored tobacco products a significant public
health concern. These findings have important implica-
tions for future policies and prevention campaigns aimed
at deterring the uptake of menthol tobacco use among
vulnerable and at-risk groups who have disproportionately
high rates of use. Even though it is clear that menthol pro-
vides an “extra something” [75], and may contribute to
mental health beyond just nicotine alone, the mechanisms
underlying menthol’s link to depression and anxiety, nico-
tine addiction, and initiation and progression are not clear.
Policies should be put in place to ban or further restrict
the sale and marketing of menthol tobacco to youth and
young people given these risks.
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